Paromomycin Sulfate

A to Z Drug Facts

Paromomycin Sulfate

  Action
  Indications
  Contraindications
  Route/Dosage
  Interactions
  Lab Test Interferences
  Adverse Reactions
  Precautions
Patient Care Considerations
  Administration/Storage
  Assessment/Interventions
  Patient/Family Education


(par-oh-moe-MY-sin SULL-fate)
Humatin
Class: Anti-infective/Amebicide/Aminoglycoside

 Action Inhibits production of protein in bacteria, causing bacterial cell death.

 Indications Treatment of acute and chronic intestinal amebiasis. Adjunctive therapy in management of hepatic coma. Unlabeled use(s): Treatment of other parasitic infections.

 Contraindications Intestinal obstruction; extraintestinal amebiasis; hypersensitivity to aminoglycosides.

 Route/Dosage

Intestinal Amebiasis

ADULTS & CHILDREN: PO 25 to 35 mg/kg/day in 3 divided doses with meals for 5 to 10 days.

Hepatic Coma

ADULTS: PO 4 g/day in divided doses at regular intervals for 5 to 6 days.

 Interactions

Digoxin: May reduce rate and extent of digoxin absorption; this may be offset by decreased digoxin metabolism. Methotrexate: Decreased absorption of methotrexate. Neuromuscular blockers: Increased action of both depolarizing and nondepolarizing neuromuscular blocking agents, may prolong need for respiratory support. Neurotoxic, nephrotoxic, or ototoxic medications (eg, polypeptide antibiotics): Additive adverse effects may occur with concurrent or sequential administration of medications with similar toxic profiles.

 Lab Test Interferences None well documented.

 Adverse Reactions

GI: Nausea; vomiting; abdominal cramps; anorexia; epigastric burning; pruritus ani; diarrhea. OTHER: Malabsorption syndrome.

 Precautions

Pregnancy: Category D. Lactation: Excreted in breast milk. Muscular disorders: Patients with muscular disorders such as myasthenia gravis or parkinsonism may have worsening of their disease because of potential effect of aminoglycosides on neuromuscular junction. Ototoxicity and renal damage: Inadvertent absorption through ulcerative bowel lesions may be associated with significant hearing and kidney damage. Superinfection: Prolonged or repeated therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms and secondary infections.


PATIENT CARE CONSIDERATIONS


 Administration/Storage

 Assessment/Interventions

OVERDOSAGE: SIGNS & SYMPTOMS
  Neurotoxicity, nephrotoxicity, ototoxicity

 Patient/Family Education

Books@Ovid
Copyright
© 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts